Supramaximal High-Intensity Interval Training in People With and Without Chronic Obstructive Pulmonary Disease

Summary

Beyond pulmonary complications, COPD presents with extrapulmonary manifestations including reduced cognitive, cardiovascular, and muscle function. While exercise training is the cornerstone in the non-pharmacological treatment of COPD, there is a need for new exercise training methods.

The COPD-HIIT trial intend to investigate the effects and mechanisms of 12 weeks supramaximal high-intensity interval-training (HIIT) compared to moderate intensive continous training (MICT) in people with COPD and matched healthy controls on important clinical outcomes.

The trial also intends to compare the effects of 24 months of exercise training (supramaximal HIIT or MICT) to usual care in people with COPD on brain health, cardiorespiratory fitness and muscle power; in people with COPD.

Conditions

• COPD
• Healthy Controls

Interventions

OTHER

Exercise training on a stationary bicycle

Training is performed two to three times per week for a total of 30 sessions using a group format. Both regimens start with a five-minute warm-up and ends with a five-minute cool-down, performed at an intensity corresponding to 30% of the maximal work rate achieved during a CPET (i.e., max aerobic power \[MAP\]) with a self-selected pedalling cadence of 50-70 revolutions per minute (RPM). All exercise sessions will be held and supervised by an experienced health care professional, i.e. physiotherapists or other health professional. The different types of exercise training is described under the specific arm. Following the first 12-week training period, participants with COPD will enter a 21-month maintenance phase. They will continue to exercise using the same training modality (HIIT or MICT) as during the first 12-weeks but can select between three different settings to continue their training: "Home", "Outpatient", or "Mix" setting.

Sponsors & Collaborators

• Hasselt University

  collaborator OTHER

• Swedish Heart Lung Foundation

  collaborator OTHER

• European Research Council

  collaborator OTHER

• The Swedish Research Council

  collaborator OTHER_GOV

• Ziekenhuis Oost-Limburg

  collaborator OTHER

• Strategic Research Area - Health Care Science

  collaborator UNKNOWN

• Umeå University

  lead OTHER

Principal Investigators

• André Nyberg, PhD · Umeå University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

60 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2023-11-09

Primary Completion

2028-12-31

Completion

2028-12-31

Countries

• Belgium
• Sweden

Study Locations